HIMS — Hims & Hers Health, Inc.

HIMS & HERS Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: $618 million, up 28% year-over-year.
• Full Year Revenue: $2.35 billion, a 59% increase from 2024.
• Subscribers: Over 2.5 million, with 65% utilizing personalized treatments.
• Monthly Revenue per Subscriber: Increased 11% year-over-year to $83.
• Adjusted EBITDA: $66 million in Q4, with a margin of 11%; full-year adjusted EBITDA increased 80% to $318 million, with a margin of 14%.
• Net Income: $128 million for the year, reflecting strong profitability.
• Free Cash Flow: Generated $57 million in 2025, with $929 million in cash and investments on the balance sheet.

2. Strategic Updates and Business Highlights:

• Expansion of Offerings: Successful launches in 2025 included hormone therapies and a new Labs offering, with expectations for these to reach $100 million in revenue.
• International Growth: Acquisitions of ZAVA and Livewell expanded presence in Europe and Canada, with plans to acquire Eucalyptus to enter Australia and Japan.
• Focus on Personalized Care: Continued emphasis on personalized solutions across various health specialties, including weight loss, sexual health, and dermatology.
• Technological Investments: Significant investments in AI, diagnostics, and infrastructure to enhance service delivery and consumer engagement.

3. Forward Guidance and Outlook:

• Q1 2026 Revenue Guidance: Expected between $600 million to $625 million, a 2% to 7% year-over-year increase.
• Full Year 2026 Revenue Guidance: Anticipated between $2.7 billion to $2.9 billion, representing a 15% to 24% increase.
• Adjusted EBITDA for 2026: Expected between $300 million and $375 million, with a margin of approximately 12%.
• International Revenue Contribution: Anticipating at least $200 million from international markets, including contributions from the Eucalyptus acquisition.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Scrutiny: Concerns regarding compounded GLP-1s may impact growth, with a projected $65 million revenue headwind in Q1 2026 due to changes in shipping cadences.
• Gross Margin Decline: Gross margins fell by approximately 2 points in Q4 due to increased contributions from international markets and costs associated with new specialty launches.
• Market Competition: The evolving landscape of weight loss treatments and potential regulatory changes pose risks to growth and profitability.

5. Notable Q&A Insights:

• International Expansion Strategy: The company aims to unify its brand across key markets and anticipates significant international revenue growth, targeting $1 billion in incremental revenue in the coming years.
• Durability of Weight Loss Business: Despite potential headwinds from GLP-1 scrutiny, management remains confident in the long-term growth of the weight loss segment, citing a diverse range of upcoming treatments.
• Marketing Efficiency: The company is seeing improved customer acquisition costs and lifetime value as it expands into broader health categories, enhancing overall retention and engagement.
• Investment Strategy: Future investments will be stage-gated, focusing on scaling successful new offerings and enhancing technology capabilities to support proactive care.

Overall, Hims & Hers demonstrated strong financial performance in 2025, with significant growth in subscribers and revenue. Strategic expansions and technological investments position the company well for future growth, although regulatory challenges and market dynamics present ongoing risks.